Thymalin in patients with severe trauma

K. Ya. Gurevich, V. Kh. Khavinson, V. G. Morozov · 1984 · Vestn Khir Im I I Grek. 1984;132(2):52–54. PMID 6547012.

Human study · design details unresolvedEnglish abstractSource linked

Reported findings and study design

Narrative findings; numerical extraction incomplete

Results · Original indexed abstract
Measure	Result	Comparison, timing and statistics
Clinical course and immune indices	Authors describe improvement during combined care. No numerical outcome is given.

Source for these results ↗ · Reviewed 2026-11-10

For research and education. Consult a qualified clinician for medical advice.

Study limitations and source details

Study limitations

The abstract gives no comparison arm, event counts, effect estimates or adverse-event data. It does not isolate Thymalin’s contribution.

Source access

Original indexed abstract reviewed. Full methods, dose and effect sizes unavailable.

Source reviewed 2026-11-10.

Open source ↗

Citation and original source

Original source: K. Ya. Gurevich, V. Kh. Khavinson, V. G. Morozov. Thymalin in patients with severe trauma Vestn Khir Im I I Grek. 1984;132(2):52–54. PMID 6547012. 1984.

Molekul research summary: https://molekul.io/research/thymalin-gurevich-trauma-1984. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Bibliography entry

Related compound profiles

Thymalin

Thymus-derived peptide mixture with historical Russian studies in autoimmune cytopenias and thyroiditis, alongside other treatments. It is distinct from synthetic Thymogen and Thymodepressin.

Editorial policy and evidence standards